Related Experiment Video
Updated: Dec 22, 2025
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
[Synergistic Effect of Immune Checkpoint Blockade Inhibition Therapy by Modulating T Cell Metabolism]
Moto Shimazaki1, Kenji Chamoto
1Dept. of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University.
Abstract:
Immune checkpoint blockade inhibition is a therapy which interferes with inhibitory signals placed upon immune cells, thereby eliciting anti-tumor responses. Although programmed death-1(PD-1)blockade therapy has been shown to be highly effective in clinical use, certain population of patients still fail to respond. Therefore, it is critical to determine how therapeutic efficacy of checkpoint inhibition can be enhanced. Recently, it has been shown that intracellular metabolism plays an important role in T cell differentiation and function. Because an effective tumor response relies on the differentiation of tumor-responsive effector cytotoxic T lymphocytes(CTLs), understanding such mechanisms will be essential for developing an improved therapeutic approach. Experiments on tumor-bearing mice have displayed strong anti-tumor responses upon combination therapy ofPD -1 blockade and enhanced mitochondrial metabolism, through increased production ofreactive oxygen species(ROS); upregulation ofmechanistic target ofrapamycin(mTOR)and AMP-activated protein kinase(AMPK); and upregulation ofperoxisome proliferator-activated receptor gamma coactivator 1-alpha(PGC-1a). In addition, the use of bezafibrate, a peroxisome proliferator-activated receptor(PPAR)agonist, in combination with PD-1 blockade resulted in improved effector function in CTLs. In this review, we will explore the mechanism behind T cell metabolism under the context ofcheckpoint blockade therapy, as well as how modulating T cell metabolism yields synergistic anti-tumor effects in combination with PD-1 blockade therapy.
Insights
Enhancing immune checkpoint blockade therapy involves targeting T cell metabolism. Combining PD-1 blockade with enhanced mitochondrial function, including ROS production and PGC-1a upregulation, boosts anti-tumor responses.
Area of Science:
- Immunology
- Cancer Biology
- Metabolic Regulation
Background:
- Immune checkpoint blockade, particularly programmed death-1 (PD-1) blockade, is effective against tumors but faces non-response in some patients.
- Intracellular metabolism critically influences T cell differentiation and function, impacting anti-tumor immunity.
- Enhancing T cell effector function is crucial for improving therapeutic efficacy in cancer treatment.
Purpose of the Study:
- To investigate mechanisms for enhancing the therapeutic efficacy of immune checkpoint inhibition.
- To explore the role of T cell metabolism in the context of PD-1 blockade therapy.
- To understand how modulating T cell metabolism can synergize with PD-1 blockade for improved anti-tumor effects.
Main Methods:
- Utilized tumor-bearing mouse models to assess combination therapies.
- Investigated the effects of enhanced mitochondrial metabolism on T cell function.
- Examined the impact of bezafibrate, a peroxisome proliferator-activated receptor (PPAR) agonist, combined with PD-1 blockade.
Main Results:
- Combination therapy of PD-1 blockade and enhanced mitochondrial metabolism showed strong anti-tumor responses in mice.
- Observed increased reactive oxygen species (ROS) production, and upregulation of mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a).
- Bezafibrate combined with PD-1 blockade improved effector function in cytotoxic T lymphocytes (CTLs).
Conclusions:
- Modulating T cell metabolism, particularly enhancing mitochondrial function, synergizes with PD-1 blockade to elicit potent anti-tumor responses.
- Targeting metabolic pathways offers a promising strategy to overcome resistance and improve the effectiveness of checkpoint inhibition therapies.
- Further research into T cell metabolism is essential for developing novel and improved cancer treatment approaches.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:17The Tumor Microenvironment
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity